Phil Ball

Phil Ball, PhD, has over 20 years of international biopharma experience in business development, alliance management, product development, and global health policy.

Prior to Tolerance Bio, Phil was VP of Alliance Management and Business Development for Provention Bio until its acquisition by Sanofi. Earlier in his career, he held roles of increasing responsibility at Allergan, Actavis, Watson Pharmaceuticals, and Eden Biodesign.

Phil received his BSc in biochemistry from the University of Manchester and PhD in biochemistry from the University of Liverpool.